12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Company News  |  Deals

Onyx, University of Texas M.D. Anderson Cancer Center deal

The university will conduct preclinical and clinical studies under a non-exclusive, two-year deal to research potential treatments for multiple myeloma (MM) and lymphoma, including Onyx's proteasome inhibitors carfilzomib and oprozomib (formerly ONX 0912). The partners...

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >